GDTC CytoMed Therapeutics Limited
USHealthcareAs of 2026-07-10 16:00
Why GDTC matters now
CytoMed Therapeutics Limited (GDTC) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.03 with +5.10% on the session and $12.2M in market capitalization; recent performance reads 1-month -9.09% and YTD -17.91%.
The latest financial table shown here is Q4 2025, with revenue of $167.9K, net income of $-1.7M, and EPS of $-0.14. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -36.6%.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Choo Chee Kong filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.56
P/S
33.04
EV/EBITDA
-3.08
DCF Value
$-0.51
FCF Yield
-36.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-35.3%
Operating Margin
-1048.8%
Net Margin
-1070.9%
ROE
-73.1%
ROA
-68.3%
ROIC
-72.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $167.9K | $-1.7M | $-0.14 |
| FY 2025 | $319.2K | $-3.9M | $-0.33 |
| Q2 2025 | $134.9K | $-1.1M | $-0.10 |
| Q1 2025 | $134.7K | $-1.1M | $-0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
SG
Exchange
—
Beta
-0.04
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.